Freeport-McMoRan Inc vs Cassava Sciences Inc — how do they compare? Freeport-McMoRan Inc trades at $69.25 (market cap $98.71B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Freeport-McMoRan Inc is far larger — about 2067.2× Cassava Sciences Inc's market cap, and Freeport-McMoRan Inc pays a 0.85% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FCX | FLNA | |
|---|---|---|
Market Cap | $98.71B | $47.75M |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $4.64 |
52-Week Low | $35.34 | $0.87 |
Enterprise Value | $104.99B | -$34.93M |
Dividend Yield | 0.85% | — |
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, up 2.1% today, with a bullish technical signal from moving averages but overbought RSI near 86. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.68 above the $0.60 forecast. Revenue reached $25.92B in 2025, with net income margin improving to 8.5%. Recent news highlights progress at the Grasberg mine and strong copper prices supporting operations.
Outlook is positive with a consensus price target of $73.85, implying 6% upside, backed by 61% analyst buy ratings. Risks include reliance on commodity cycles and potential volatility from economic shifts. The company's solid cash flow and debt reduction trend provide stability, but investors should monitor copper market dynamics for sustained growth.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Trailing returns across standard periods
Latest headlines on both assets
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →